Table 1.
Baseline characteristics of matched patients with relapsed or refractory acute myeloid leukemia who received 10-day decitabine with venetoclax (DEC10-VEN), and intensive chemotherapy (IC)
| Patient characteristics | DEC10-VEN (N=65) | IC (N=130) |
p |
|---|---|---|---|
| Age, years | 64 [18–85] | 58 [19–80] | .113 |
| <60 years | 26 (40) | 74 (57) | .038 |
| Male sex | 39 (60) | 72 (55) | .539 |
| AML type | |||
| Primary refractory AML | 28 (43) | 54 (42) | .837 |
| Relapsed AML | 37 (57) | 76 (58) | .891 |
| Secondary AML from AHD | 11 (17) | 21 (16) | |
| ECOG performance status | |||
| 0–1 | 46 (71) | 95 (73) | .734 |
| ≥2 | 19 (29) | 35 (27) | |
| Bone marrow blasts, % | 34 [1–96] | 35 [0–98] | .536 |
| ELN 2017 cytogenetic group | |||
| Favorable | 0 (0) | 0 (0) | .958 |
| Intermediate | 41 (63) | 80 (62) | |
| Adverse | 24 (37) | 50 (38) | |
| Mutations | |||
| NPM1 | 14 (22) | 15 (12) | .605 |
| FLT3-ITD/TKD | 16 (25) | 34 (26) | |
| IDH1/2 | 11 (17) | 28 (22) | |
| TP53 | 18 (28) | 32 (25) | |
| RUNX1 | 12 (18) | 22 (17)1 | |
| ASXL1 | 10 (15) | 14 (11)1 | |
| ELN 2017 risk group | |||
| Favorable | 10 (15) | 11 (8) | .302 |
| Intermediate | 12 (18) | 30 (23) | |
| Adverse | 43 (66) | 89 (68) | |
| No. of prior therapies | 2 [1–8] | 2 [1–10] | .721 |
| Prior therapies | |||
| HMA only | 16 (25) | 24 (18) | .214 |
| IC only | 31 (48) | 53 (41) | |
| IC and HMA | 16 (25) | 53 (41) | |
| SCT | 18 (28) | 36 (28) |
Results reported as n (%), or median [range]. AHD = antecedent hematological disorder, ELN = European LeukemiaNet. IC = intensive chemotherapy, HMA = hypomethylating agent, SCT = allogeneic stem cell transplantation.
1.
RUNX1 and ASXL1 status was unknown for 9 patients.